Towards Degrader-Antibody Conjugates
Antibody drug conjugates (ADCs) and protein degraders are two unique classes of cancer-targeted therapeutic agents. This collection includes research and review articles on the preclinical to early clinical development of novel ADCs and protein degraders. Degrader-antibody conjugates are currently in preclinical development and represent the next frontier of antibody-conjugated therapeutics. Danielle Large, PhD, Assistant Editor, Molecular Cancer Therapeutics ([email protected]).
Reviews
Biomarkers for Antibody–Drug Conjugates in Solid Tumors
Jalissa Katrini; Laura Boldrini; Celeste Santoro; Carmine Valenza; Dario Trapani; Giuseppe Curigliano
Doi: 10.1158/1535-7163.MCT-23-0482
Reviews
PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer
Kailee A. Rutherford; Kirk J. McManus
Doi: 10.1158/1535-7163.MCT-23-0747
Commentary
Bruton Tyrosine Kinase Degraders in B-Cell Malignancies
Tiana Huynh; Sonia Rodriguez-Rodriguez; Alexey V. Danilov
Doi: 10.1158/1535-7163.MCT-23-0520